Cargando…
Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers
The National Comprehensive Cancer Network (NCCN) recently published a task force report on the evaluation of the clinical utility of tumor biomarkers in oncology. In this report, common terminology and the use of levels of evidence scores to aid the evaluation of biomarker tests in oncology were pro...
Autores principales: | Berghoff, Anna Sophie, Stefanits, Harald, Heinzl, Harald, Preusser, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663460/ https://www.ncbi.nlm.nih.gov/pubmed/22720693 http://dx.doi.org/10.5414/NP300511 |
Ejemplares similares
-
Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers
por: Berghoff, Anna S., et al.
Publicado: (2013) -
Clinical neuropathology practice news 2-2012: BRAF V600E testing
por: Capper, David, et al.
Publicado: (2012) -
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
por: Bienkowski, Michal, et al.
Publicado: (2015) -
Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?
por: Berghoff, Anna S., et al.
Publicado: (2012) -
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
por: Preusser, Matthias, et al.
Publicado: (2015)